Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Hemostasis01:24

Disorders of Hemostasis

1.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
1.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.3K
Introduction to Hemostasis01:05

Introduction to Hemostasis

12.1K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
12.1K
Venous Thrombosis I: Introduction01:30

Venous Thrombosis I: Introduction

151
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
151
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

167
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
167
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

11.1K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
11.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Explaining recurrent thrombotic events and predicting bleeding in critically ill neonates diagnosed with umbilical central venous catheter-related portal vein thrombosis.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Apixaban for the treatment of venous thromboembolic events in paediatric patients: an open-label, multicentre, randomised, controlled descriptive trial.

The Lancet. Haematology·2026
Same author

Infection-Triggered Complex Coagulopathy With Lupus Anticoagulant, Heparinoid Inhibitors, and ITP-Like Thrombocytopenia Associated With Bleeding: Successful IVIG Treatment Monitored by Thromboelastography.

International journal of laboratory hematology·2026
Same author

ASH/ISTH 2026 guidelines for anticoagulant prophylaxis in pediatric patients at risk of venous thromboembolism.

Blood advances·2026
Same author

Establishment of Age-Specific Reference Intervals for 16 Coagulation Parameters in Chinese Children Using Sysmex CN-6000 Analyzer: A Cross-Sectional Study.

Health science reports·2026
Same author

Rivaroxaban in Chinese children with giant coronary artery aneurysms after Kawasaki disease.

Research and practice in thrombosis and haemostasis·2025

Related Experiment Video

Updated: Dec 5, 2025

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber
09:55

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber

Published on: May 30, 2016

9.2K

Coagulation issues in vascular anomalies.

Kiersten W Ricci1, Leonardo R Brandão2

  • 1Hemangioma and Vascular Malformation Center, Division of Hematology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Avenue, MLC 7015, Cincinnati 45229, OH, United States.

Seminars in Pediatric Surgery
|October 18, 2020
PubMed
Summary
This summary is machine-generated.

Vascular anomalies often cause coagulopathy, a bleeding disorder. Understanding Kasabach-Merritt phenomenon (KMP) and localized intravascular coagulopathy (LIC) is crucial for surgical planning and patient care.

Keywords:
AnticoagulationCoagulopathyKasabach-Merritt phenomenonVascular anomalyVascular malformation

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.0K

Related Experiment Videos

Last Updated: Dec 5, 2025

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber
09:55

Tissue Engineering by Intrinsic Vascularization in an In Vivo Tissue Engineering Chamber

Published on: May 30, 2016

9.2K
In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
09:19

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

9.5K
In Vitro Thrombosis Test for Ventricular Assist Devices
09:15

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

1.0K

Area of Science:

  • Hematology
  • Vascular Surgery
  • Pediatric Surgery

Background:

  • Vascular anomalies, including tumors and malformations, are frequently linked to coagulopathy.
  • Hematologic abnormalities associated with vascular anomalies require careful pre-operative assessment.
  • Kasabach-Merritt phenomenon (KMP) and localized intravascular coagulopathy (LIC) represent complex coagulopathies in this context.

Purpose of the Study:

  • To review the main features of vascular anomaly-associated coagulopathies.
  • To highlight clinical aspects relevant to surgical management.
  • To emphasize the importance of distinguishing between KMP and LIC phenotypes.

Main Methods:

  • Literature review of vascular anomalies and associated coagulopathies.
  • Summary of clinical presentations and diagnostic criteria for KMP and LIC.
  • Analysis of management strategies, particularly in the peri-operative setting.

Main Results:

  • Coagulopathy is a common complication of vascular tumors and malformations.
  • KMP and LIC are distinct phenotypes of coagulopathy associated with specific vascular anomalies.
  • Expert hematologic consultation is vital for managing these complex cases.

Conclusions:

  • Accurate recognition and classification of coagulopathies are essential for effective surgical planning.
  • Understanding the nuances of KMP and LIC improves patient outcomes.
  • Multidisciplinary collaboration, including hematologists, optimizes care for patients with vascular anomalies and coagulopathy.